GE9 GER Week ended 24 Jul 2026

Weekly Investor Report

Name: GE9 weekly investor report
Creator: Sharemaestro
License: https://sharemaestro.com/data-license/

GENMAB AS N · Healthcare · Biotechnology

Open interactive chart View report data

Latest close 252.2 EUR

1.0% latest week

Weekly setup

Mixed setup

The weekly trend is not active. Price is 3.5% above the Trend Line and sits at 30.3% of its 52-week range. The latest completed week returned 1.0%, after a 10.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100.

Setup score 48 out of 100

Latest Close 252.2 EUR 24 Jul 2026

1W Return 1.0% latest completed week

4W Return 10.2% short-term follow-through

12W Return 11.7% quarterly tape

Trend Breadth 0.0% 0 of 52 weeks active

Volume Ratio 1.8x vs 13-week average

What is working

Price is above the Trend Line, keeping the weekly tape constructive.
Activity pressure is positive on the latest completed week.
Volume is elevated versus the 13-week average, confirming attention.
Next-week expectancy is positive at 55.79% based on similar historical setup states.

What could go wrong

The trend backdrop is inactive, so price action has not confirmed a constructive regime.
Price is below Fair Value, so the market is still discounting the latest tape.
Activity pressure is weak, so confirmation is not yet broad enough.
The share remains more than 20% below its 52-week high.

What to watch next

Trend Line remains the key weekly regime level.
Activity pressure is the gauge to monitor for confirmation or fade.
A volume ratio above 1.5x would show stronger participation in the next move.

Price follow-through 1.0% Latest completed week; four-week move 10.2%. Indicator stack 0/93 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 55.79% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 50/100 1 relevant articles in the latest sentiment read.

01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 3.5% above the Trend Line and sits at 30.3% of its 52-week range. The latest completed week returned 1.0%, after a 10.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value

Price Trend Line Fair Value

Position in the 52-week range

Close Trend Fair

208.2 EUR 30.3% 353.5 EUR

Range location30.3%Shows where the latest close sits between the 52-week low and high.

Trend distance3.5%Price premium or discount versus the weekly Trend Line.

Fair-value gap-9.3%Premium demand or model discount versus Sharemaestro Fair Value.

High-water gap-28.7%Distance from the latest 52-week high.

02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.8x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction

30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul

Up week Down week

Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3112-week average 0.19

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.

Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.

Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.

Activity pressure0.31Current proprietary activity-pressure read.

Buy signals0Accumulation signal count in the latest 12 weeks.

Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 10.2% over four weeks, 11.7% over 12 weeks, and -17.8% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W1.0%

4W10.2%

12W11.7%

26W-12.2%

52W-17.8%

Active trend streak0 weeks

Active weeks in one year0

Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership

Pressure0.46Latest activity-pressure read.

Pressure change435.1%Four-week change in activity pressure.

Leadership-24.61Latest relative-leadership reading.

RS change27.8%Four-week change in relative leadership.

04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis

Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 91% Model confidence 87%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength24/100Blend of value, momentum, and quality. Underlying universe rank 77; rank 1 is best.

Value28/100Relative valuation strength. Underlying universe rank 73; rank 1 is best.

Quality80/100Profitability and accounting quality. Underlying universe rank 21; rank 1 is best.

Momentum19/100Medium-term price momentum. Underlying universe rank 82; rank 1 is best.

Growth69/100Revenue and earnings growth. Underlying universe rank 32; rank 1 is best.

How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E: 18.9x
Price / sales: 4.0x
EV / EBITDA: 15.0x
Free-cash-flow yield: 4.5%

Business quality

Margins and the return generated on invested capital.

Gross margin: 93.3%
Operating margin: 33.0%
Free-cash-flow margin: 22.4%
Return on invested capital: 10.1%

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth: 19.2%
EPS growth: -12.3%
Free-cash-flow growth: 4.5%
Piotroski F-score: 4/9

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield: -
Buyback yield: 3.2%
Shareholder yield: 3.2%
Net debt / EBITDA: 3.0x

05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 1 relevant articles.

0 positive · 1 neutral · 0 negative

Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal

06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.

Options expected move-Nearest-chain priced movement where available.

52-week drawdown-28.7%Distance below the 52-week high.

13-week volatility4.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

30 Jan 27 Feb 27 Mar 24 Apr 22 May 19 Jun 24 Jul

Weeks higher12 of 2614 weeks finished lower.

Best week+9.2%Week of 3 Jul.

Worst week-7.7%Week of 20 Mar.

Latest week+1.0%Week of 24 Jul.

Shape of recent returns

Strong gains3

Modest gains9

Flat weeks0

Modest losses8

Sharp losses6

Recent vol4.1%13-week weekly-return volatility.

Base vol5.3%52-week weekly-return volatility.

Up/down split22/23Count of positive and negative weeks in the 52-week window.

Average skew3.9% / -4.2%Average positive week versus average negative week.

07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

SectorDE Healthcare

4-week rank9 / 78

Group average1.5%

Trend breadth38.5%

Trend38.5%active weekly trend signals

MD64.1%positive activity pressure

RS43.6%positive relative leadership

Four-week leaders

B72 · GER62.8%SBX · GER16.8%DRW3 · GER16.2%SBS · GER11.3%VME · GER11.3%

IndustryDE Biotechnology

4-week rank2 / 11

Group average5.1%

Trend breadth36.4%

Trend36.4%active weekly trend signals

MD45.5%positive activity pressure

RS36.4%positive relative leadership

Four-week leaders

B72 · GER62.8%GE9 · GER10.2%RGO · GER4.5%PSH0 · GER3.4%FYB · GER0.0%

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape40/100

Trend, activity pressure, participation, and risk combine to a 40/100 tape read.

Indicator analysis28/100

Latest 12-week confirmation: trend 0/12, activity pressure 8/12, relative leadership 0/12.

Activity pressure 0.31; No reversal markers Next-Week ExpectancyPositive 55.79%

Next-week expectancy is positive with a 55.79% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors37/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 14; Small Cap Core rank 81 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 1 relevant articles.

Genmab A/S Revenue Breakdown – FWB:GE9 Insiders50/100

No recent insider transaction evidence is stored.

Earnings50/100

No stored earnings event is currently attached to this ticker.

Week	Close	Return	Trend Line	Fair Value	Pressure	Leadership	Volume	Trend
24 Jul 2026	252.2 EUR	1.0%	243.7 EUR	278.0 EUR	0.46	-24.61	619	Off
17 Jul 2026	249.7 EUR	-3.2%	244.8 EUR	278.4 EUR	0.38	-25.66	49	Off
10 Jul 2026	257.9 EUR	3.2%	245.7 EUR	278.9 EUR	0.31	-24.92	145	Off
3 Jul 2026	250.0 EUR	9.2%	246.3 EUR	279.3 EUR	0.23	-30.12	1.1K	Off
26 Jun 2026	228.9 EUR	5.7%	247.0 EUR	279.8 EUR	0.09	-34.08	102	Off
19 Jun 2026	216.5 EUR	0.4%	248.6 EUR	280.6 EUR	0.06	-39.38	0	Off
12 Jun 2026	215.7 EUR	-0.4%	250.2 EUR	281.8 EUR	0.08	-39.71	0	Off
5 Jun 2026	216.6 EUR	-4.7%	251.7 EUR	282.9 EUR	0.10	-40.71	692	Off
29 May 2026	227.2 EUR	-1.6%	255.5 EUR	284.1 EUR	-0.20	-39.63	51	Off
22 May 2026	231.0 EUR	0.2%	259.0 EUR	285.2 EUR	-0.48	-39.08	232	Off
15 May 2026	230.5 EUR	6.4%	262.3 EUR	286.2 EUR	-0.79	-37.85	704	Off
8 May 2026	216.6 EUR	-4.0%	265.7 EUR	287.3 EUR	-1.06	-43.41	656	Off
1 May 2026	225.7 EUR	-1.6%	269.5 EUR	288.7 EUR	-0.95	-	124	Off
24 Apr 2026	229.3 EUR	-5.3%	273.2 EUR	289.9 EUR	-0.94	-	303	Off

How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.